Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endocrine therapy for prostate cancer.

F Labrie1

  • 1Department of Molecular Endocrinology, CHUL Research Center, Quebec, Canada.

Endocrinology and Metabolism Clinics of North America
|December 1, 1991
PubMed
Summary

Advanced prostate cancer treatment is improved by blocking androgen receptors and using castration. This combination therapy, including antiandrogens and luteinizing hormone-releasing hormone agonists, prolongs patient response duration and survival.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential expression and regulation of connexin-43 and cell-cell coupling in myocytes from the circular and longitudinal layers of bovine myometrium.

Endocrinology·1995
Same author

Local and systemic reduction by topical finasteride or flutamide of hamster flank organ size and enzyme activity.

The Journal of investigative dermatology·1995
Same author

Anti-androgens in treatment of prostate cancer.

Lancet (London, England)·1995
Same author

Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard.

The Prostate·1995
Same author

The human type II 17 beta-hydroxysteroid dehydrogenase gene encodes two alternatively spliced mRNA species.

DNA and cell biology·1995
Same author

Interleukin-6 inhibits the potent stimulatory action of androgens, glucocorticoids and interleukin-1 alpha on apolipoprotein D and GCDFP-15 expression in human breast cancer cells.

International journal of cancer·1995

Area of Science:

  • Endocrinology
  • Oncology
  • Cancer Biology

Background:

  • Prostate cancer is the most common cancer affecting men globally.
  • Testes produce 60% of adult male androgens, with the remaining 40% synthesized in peripheral tissues like the prostate from adrenal precursors.
  • This highlights the role of peripheral androgen synthesis in prostate cancer progression.

Purpose of the Study:

  • To investigate the efficacy of a combination therapy for advanced prostate cancer.
  • To evaluate the impact of androgen receptor blockade and castration on treatment outcomes.

Main Methods:

  • Utilizing a combination therapy involving a pure androgen receptor blocker (antiandrogen) and castration (medical via luteinizing hormone-releasing hormone agonist or surgical orchiectomy).

Main Results:

  • Demonstrated a significant prolongation in the duration of response for patients with advanced prostate cancer.
  • Showed a statistically significant improvement in survival rates for the first time with this combined therapeutic approach.

Conclusions:

  • Combination therapy of antiandrogens and castration offers a novel and effective strategy for managing advanced prostate cancer.
  • This approach provides a new paradigm for improving treatment outcomes and extending survival in advanced prostate cancer patients.

Related Experiment Videos